Cita APA

Pérez-García, J. M., Gil-Gil, M. J., Ruiz Borrego, M., Di Cosimo, S., Bellet Ezquerra, M., & Dalenc, F. (2023). Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.

Citación estilo Chicago

Pérez-García, José Manuel, Miguel J. Gil-Gil, Manuel Ruiz Borrego, Serena Di Cosimo, Meritxell Bellet Ezquerra, y Florence Dalenc. Palbociclib With Fulvestrant or Letrozole in Endocrine-Sensitive Patients With HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. 2023.

Cita MLA

Pérez-García, José Manuel, et al. Palbociclib With Fulvestrant or Letrozole in Endocrine-Sensitive Patients With HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. 2023.